Herpes Simplex Virus (HSV) Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Virus Type (HSV-1 v/s HSV-2), By Treatment (Drugs v/s Vaccines), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region
Global Herpes Simplex Virus (HSV) Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing aging population and increased cases of diseases like Herpes Simplex infection and HIV. Additionally, the growing usage of unhygienic practices in emerging countries, along with rising investments in research and development activities, have significantly increased the demand for herpes simplex virus treatment across different parts of the globe. Moreover, the growing demand for efficient treatment for rare conditions is further expected to increase the demand for herpes simplex virus treatment, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using new treatments, along with increasing healthcare expenditure on HSV treatment across the globe, is further expected to support the herpes simplex virus treatment market during the forecast period.
Increasing prevalence of HSV Infection
The increasing prevalence of Herpes Simplex Virus infection, along with the increasing rate of hospital-acquired infection and rapid mutations in the microorganism leading to new strains, are the major factors that will drive the growth of the market during the forecast period. Furthermore, the increasing transmission of infectious disease and lack of cleanliness in underdeveloped and developing regions are further propelling the herpes simplex virus infection treatment market during the forecast period. According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection. The rising burden of HSV encephalitis is expected to propel the market in this segment. As per the National Organization for Rare Disorders, the prevalence of acute encephalitis in the U.S. is around 2,000 cases per year, and it includes around 10% of total cases of encephalitis occurring in the U.S. Additionally, the rising focus on drug development, increasing demand for precision medicine along with high adoption of home care settings and point-of-care diagnostics, growing investments in research and development activities are expected to drive global market growth during the forecast period.
Growing Healthcare Expenditure
The pharma and healthcare sector are rapidly growing with technological innovations, increasing healthcare spending, and improving healthcare facilities and systems, which is expected to create lucrative growth during the forecast period. Many hospitals, ambulatory surgical care centers, and clinics are adopting advanced devices and equipment across the globe, which will enhance the growth of the market. Increasing initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is expected to boost market growth during the forecast period. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).
Market Segmentation
The global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, treatment, route of administration, distribution channel, and by region. Based on the virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global herpes simplex virus treatment market on account of the growing demand for treatments due to the increasing prevalence of herpes simplex virus infection.
Market Players
Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.
Report Scope:
In this report, Global Herpes Simplex Virus (HSV) Treatment systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Herpes Simplex Virus (HSV) Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Increasing prevalence of HSV Infection
The increasing prevalence of Herpes Simplex Virus infection, along with the increasing rate of hospital-acquired infection and rapid mutations in the microorganism leading to new strains, are the major factors that will drive the growth of the market during the forecast period. Furthermore, the increasing transmission of infectious disease and lack of cleanliness in underdeveloped and developing regions are further propelling the herpes simplex virus infection treatment market during the forecast period. According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection. The rising burden of HSV encephalitis is expected to propel the market in this segment. As per the National Organization for Rare Disorders, the prevalence of acute encephalitis in the U.S. is around 2,000 cases per year, and it includes around 10% of total cases of encephalitis occurring in the U.S. Additionally, the rising focus on drug development, increasing demand for precision medicine along with high adoption of home care settings and point-of-care diagnostics, growing investments in research and development activities are expected to drive global market growth during the forecast period.
Growing Healthcare Expenditure
The pharma and healthcare sector are rapidly growing with technological innovations, increasing healthcare spending, and improving healthcare facilities and systems, which is expected to create lucrative growth during the forecast period. Many hospitals, ambulatory surgical care centers, and clinics are adopting advanced devices and equipment across the globe, which will enhance the growth of the market. Increasing initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is expected to boost market growth during the forecast period. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).
Market Segmentation
The global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, treatment, route of administration, distribution channel, and by region. Based on the virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global herpes simplex virus treatment market on account of the growing demand for treatments due to the increasing prevalence of herpes simplex virus infection.
Market Players
Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.
Report Scope:
In this report, Global Herpes Simplex Virus (HSV) Treatment systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:
- HSV-1
- HSV-2
- Herpes Simplex Virus (HSV) Treatment Market, By Treatment:
- Drugs
- Acyclovir
- Valacyclovir
- Famciclovir
- Others
- Vaccines
- Simplirix
- Others
- Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:
- Oral
- Intravenous
- Topical
- Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Herpes Simplex Virus (HSV) Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Herpes Simplex Virus (HSV) Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Virus Type (HSV-1 v/s HSV-2)
6.2.2. By Treatment (Drugs v/s Vaccines)
6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
6.2.2.2. By Vaccines (Simplirix, Others)
6.2.3. By Route of Administration (Oral, Intravenous, Topical)
6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
6.2.5. By Region
6.2.6. By Company (2022)
6.3. Market Map
6.3.1. By Virus Type
6.3.2. By Treatment
6.3.3. By Route of Administration
6.3.4. By Distribution Channel
7. NORTH AMERICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Virus Type (HSV-1 v/s HSV-2)
7.2.2. By Treatment (Drugs v/s Vaccines)
7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
7.2.2.2. By Vaccines (Simplirix, Others)
7.2.3. By Route of Administration (Oral, Intravenous, Topical)
7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Virus Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Virus Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Virus Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. EUROPE HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Virus Type (HSV-1 v/s HSV-2)
8.2.2. By Treatment (Drugs v/s Vaccines)
8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
8.2.2.2. By Vaccines (Simplirix, Others)
8.2.3. By Route of Administration (Oral, Intravenous, Topical)
8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Virus Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Virus Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Virus Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Virus Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Virus Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. ASIA-PACIFIC HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Virus Type (HSV-1 v/s HSV-2)
9.2.2. By Treatment (Drugs v/s Vaccines)
9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
9.2.2.2. By Vaccines (Simplirix, Others)
9.2.3. By Route of Administration (Oral, Intravenous, Topical)
9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Virus Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Virus Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Virus Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Virus Type
9.3.4.2.2. By Treatment
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Virus Type
9.3.5.2.2. By Treatment
9.3.5.2.3. By Route of Administration
9.3.5.2.4. By Distribution Channel
10. SOUTH AMERICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Virus Type (HSV-1 v/s HSV-2)
10.2.2. By Treatment (Drugs v/s Vaccines)
10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
10.2.2.2. By Vaccines (Simplirix, Others)
10.2.3. By Route of Administration (Oral, Intravenous, Topical)
10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Virus Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Virus Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Virus Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Virus Type (HSV-1 v/s HSV-2)
11.2.2. By Treatment (Drugs v/s Vaccines)
11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
11.2.2.2. By Vaccines (Simplirix, Others)
11.2.3. By Route of Administration (Oral, Intravenous, Topical)
11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Virus Type
11.3.1.2.2. By Treatment
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Virus Type
11.3.2.2.2. By Treatment
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Virus Type
11.3.3.2.2. By Treatment
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As reported)
14.5. Recent Developments
14.6. SWOT Analysis
14.6.1. Novartis International AG
14.6.2. GlaxoSmithKline, plc.
14.6.3. Sanofi SA
14.6.4. Mylan N.V.
14.6.5. Emcure Pharmaceuticals Ltd.
14.6.6. Glenmark Pharmaceuticals Inc.
14.6.7. Fresenius Kabi AG
14.6.8. Apotex Inc.
14.6.9. Viatris Inc.
14.6.10. Teva Pharmaceuticals Industries Ltd
15. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Virus Type (HSV-1 v/s HSV-2)
6.2.2. By Treatment (Drugs v/s Vaccines)
6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
6.2.2.2. By Vaccines (Simplirix, Others)
6.2.3. By Route of Administration (Oral, Intravenous, Topical)
6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
6.2.5. By Region
6.2.6. By Company (2022)
6.3. Market Map
6.3.1. By Virus Type
6.3.2. By Treatment
6.3.3. By Route of Administration
6.3.4. By Distribution Channel
7. NORTH AMERICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Virus Type (HSV-1 v/s HSV-2)
7.2.2. By Treatment (Drugs v/s Vaccines)
7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
7.2.2.2. By Vaccines (Simplirix, Others)
7.2.3. By Route of Administration (Oral, Intravenous, Topical)
7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Virus Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Virus Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Virus Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. EUROPE HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Virus Type (HSV-1 v/s HSV-2)
8.2.2. By Treatment (Drugs v/s Vaccines)
8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
8.2.2.2. By Vaccines (Simplirix, Others)
8.2.3. By Route of Administration (Oral, Intravenous, Topical)
8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Virus Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Virus Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Virus Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Virus Type
8.3.4.2.2. By Treatment
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Virus Type
8.3.5.2.2. By Treatment
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. ASIA-PACIFIC HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Virus Type (HSV-1 v/s HSV-2)
9.2.2. By Treatment (Drugs v/s Vaccines)
9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
9.2.2.2. By Vaccines (Simplirix, Others)
9.2.3. By Route of Administration (Oral, Intravenous, Topical)
9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Virus Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Virus Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Virus Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Virus Type
9.3.4.2.2. By Treatment
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Virus Type
9.3.5.2.2. By Treatment
9.3.5.2.3. By Route of Administration
9.3.5.2.4. By Distribution Channel
10. SOUTH AMERICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Virus Type (HSV-1 v/s HSV-2)
10.2.2. By Treatment (Drugs v/s Vaccines)
10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
10.2.2.2. By Vaccines (Simplirix, Others)
10.2.3. By Route of Administration (Oral, Intravenous, Topical)
10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Virus Type
10.3.1.2.2. By Treatment
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Virus Type
10.3.2.2.2. By Treatment
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Virus Type
10.3.3.2.2. By Treatment
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS (HSV) TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Virus Type (HSV-1 v/s HSV-2)
11.2.2. By Treatment (Drugs v/s Vaccines)
11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
11.2.2.2. By Vaccines (Simplirix, Others)
11.2.3. By Route of Administration (Oral, Intravenous, Topical)
11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Virus Type
11.3.1.2.2. By Treatment
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Virus Type
11.3.2.2.2. By Treatment
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Virus Type
11.3.3.2.2. By Treatment
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As reported)
14.5. Recent Developments
14.6. SWOT Analysis
14.6.1. Novartis International AG
14.6.2. GlaxoSmithKline, plc.
14.6.3. Sanofi SA
14.6.4. Mylan N.V.
14.6.5. Emcure Pharmaceuticals Ltd.
14.6.6. Glenmark Pharmaceuticals Inc.
14.6.7. Fresenius Kabi AG
14.6.8. Apotex Inc.
14.6.9. Viatris Inc.
14.6.10. Teva Pharmaceuticals Industries Ltd
15. STRATEGIC RECOMMENDATIONS
